Global Dysphagia Management Market - 2022-2029

Global Dysphagia Management Market - 2022-2029

Market Overview

The global dysphagia management market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Dysphagia is a condition that causes difficulties swallowing food or drinks. Large bits of food, little chewing, dry mouth, medicines, or eating extremely hot food are all causes of the condition. Food texture modifying products and other goods such as tubes are used to help with dysphagia management. Although some medications are available to treat dysphagia, they are not effective for all illnesses.

Market Dynamics

Advancement in the devices for the diagnosis of Dysphagia is expected to drive market growth.

Swallowscope is a mobile health-based wearable gadget that uses the swallowing sound to statistically assess swallowing abilities. It is appropriate to monitor swallowing activities because swallowing sounds may be caught constantly and throughout daily activities with no intervention. Continuous monitoring provides a higher possibility of capturing aspirations and dangerous swallow patterns. Moreover, Ultrasonography is becoming more popular as a non-invasive and radiation-free tool for evaluating swallowing function. For instance, Ultrasonographic techniques such as B-mode dynamic scanning, pixel analysis, M-mode, Doppler, 3D reconstruction, and sonoelastography have been used to assess oropharyngeal structural movement. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Dysphagia drugs and tubes have side effects and cause discomfort. For instance, the use of nasogastric tubes or PEG tubes might induce throat discomfort, abdominal cramping, abdominal swelling, diarrhea, nausea, vomiting, food and drug regurgitation, and difficulties diagnosing the actual reason for dysphagia are some of the factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The European Society for Swallowing Disorders offers suggestions to help experts in swallowing disorders in their therapeutic work. Patients with oropharyngeal dysphagia are assessed and treated during the COVID-19 pandemic while balancing the danger of oropharyngeal problems with the risk of infection for patients and healthcare professionals involved in their care. Elective, non-urgent assessments are postponed temporarily. Patients are triaged to determine whether a dysphagia assessment is required; an instrumental swallowing assessment is performed only if instrument processing is guaranteed. Clinical assessment has not provided enough diagnostic information for treatment prescription.

Moreover, Oropharyngeal dysphagia assessment and management are high-risk since it is an aerosol-generating technique. It is recommended that personal protective equipment (PPE) be worn. Telepractice is recommended, as well as compensatory therapy. Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Hospital Pharmacies segment is expected to hold the largest market share in dysphagia management market

The hospital pharmacies segment is expected to dominate in 2021. The segment is benefitted because, in hospital pharmacies, dysphagia management is utilized to treat dysphagia and avoid aspiration. It could also be an alternative or supplement to other treatments such as thickened drinks with nutritional supplements, diet changes, chest physiotherapy, oxygen therapy, or medicine to improve swallowing function. By strengthening swallow reflexes and preventing aspiration, dysphagia management medicines can minimize the risk of lung infections that cause pneumonia. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global dysphagia management market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of neurological diseases and disorders, rising geriatric population, well-established infrastructure, technological advancement in the diagnosis of dysphagia and product launches by the market players in the region are some of the factors the market is expected to boost in the forecast period. For instance, In the United States, almost one million people suffer from MS. This new prevalence rate was released in 2019, and it is more than double the previous estimate of 400,000 people in the United States who are impacted. Moreover, Thick & Easy Coffee Sticks were launched by Hormel Health Labs, a manufacturer of health and nutrition products, in July 2019 for persons with dysphagia. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the dysphagia management market are Allergan, Inc. , AstraZeneca Pharmaceuticals LP, Takeda Pharmaceuticals America, Inc., Eisai R&D Management Co., Ltd, Degania Silicone ltd, Vygon, Cook Medical, Cargill, Incorporated, CP Kelco U.S., Inc., Ingredion

AstraZeneca Pharmaceuticals LP:

Overview:

AstraZeneca Plc (AstraZeneca) is a biopharmaceutical company that discovers, produces and commercializes a wide range of prescription drugs. It focuses on therapy areas such as respiratory, cardiovascular, renal and metabolic diseases; and cancer, besides autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. It operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.

­Product Portfolio:

PRILOSEC (omeprazole magnesium): Omeprazole is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and cough.

Why Purchase the Report?

Visualize the composition of the dysphagia management market segmentation by product type, indication, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in dysphagia management market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of dysphagia management market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global dysphagia management market report would provide an access to an approx. 45+market data table, 40+figures and 160pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers